Phathom Pharmaceuticals Valuation
| PHAT Stock | USD 12.02 0.21 1.72% |
At this time, the company appears to be undervalued. Phathom Pharmaceuticals holds a recent Real Value of $14.58 per share. The prevailing price of the company is $12.02. Our model determines the value of Phathom Pharmaceuticals from analyzing the company fundamentals such as Return On Equity of -34.89, operating margin of (0.31) %, and Shares Outstanding of 78.01 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Phathom Pharmaceuticals' valuation include:
Price Book 25.3678 | Enterprise Value | Enterprise Value Ebitda (2.20) | Price Sales 6.3708 | Enterprise Value Revenue 6.984 |
Undervalued
Today
Please note that Phathom Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Phathom Pharmaceuticals is based on 3 months time horizon. Increasing Phathom Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Phathom Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 12.02, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.02 | Real 14.58 | Target 22.9 | Hype 11.94 |
The intrinsic value of Phathom Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Phathom Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Phathom Pharmaceuticals helps investors to forecast how Phathom stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Phathom Pharmaceuticals more accurately as focusing exclusively on Phathom Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Phathom Pharmaceuticals' intrinsic value based on its ongoing forecasts of Phathom Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Phathom Pharmaceuticals' closest peers.
Phathom Pharmaceuticals Cash |
|
Phathom Pharmaceuticals Total Value Analysis
Phathom Pharmaceuticals is at this time forecasted to have valuation of 1.03 B with market capitalization of 937.72 M, debt of 554.95 M, and cash on hands of 207.39 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Phathom Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.03 B | 937.72 M | 554.95 M | 207.39 M |
Phathom Pharmaceuticals Investor Information
About 78.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.76. Phathom Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Phathom Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Phathom Pharmaceuticals may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Phathom Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Phathom Pharmaceuticals has an asset utilization ratio of 14.6 percent. This implies that the Company is making $0.15 for each dollar of assets. An increasing asset utilization means that Phathom Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Phathom Pharmaceuticals Profitability Analysis
Based on Phathom Pharmaceuticals' profitability indicators, Phathom Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Phathom Pharmaceuticals' ability to earn profits and add value for shareholders.Net Loss | First Reported 2018-03-31 | Previous Quarter -75.8 M | Current Value -30 M | Quarterly Volatility 30.4 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.65 | 0.77 |
|
|
For Phathom Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Phathom Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Phathom Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Phathom Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Phathom Pharmaceuticals over time as well as its relative position and ranking within its peers.
Phathom Pharmaceuticals Earnings per Share Projection vs Actual
By analyzing Phathom Pharmaceuticals' earnings estimates, investors can diagnose different trends across Phathom Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Phathom Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Phathom Pharmaceuticals Ownership Allocation
Phathom Pharmaceuticals owns a total of 78.01 Million outstanding shares. The majority of Phathom Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Phathom Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Phathom Pharmaceuticals. Please pay attention to any change in the institutional holdings of Phathom Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Phathom Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 55.25 M. Net Loss for the year was (334.33 M) with profit before overhead, payroll, taxes, and interest of 128.42 M.About Phathom Pharmaceuticals Valuation
The stock valuation mechanism determines Phathom Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Phathom Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Phathom Pharmaceuticals. We calculate exposure to Phathom Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Phathom Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 54.4 M | 57.1 M | |
| Pretax Profit Margin | (5.45) | (5.72) | |
| Operating Profit Margin | (4.52) | (4.75) | |
| Net Loss | (5.45) | (5.72) | |
| Gross Profit Margin | 0.77 | 0.65 |
Phathom Pharmaceuticals Current Valuation Indicators
Phathom Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Phathom Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Phathom Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Phathom Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Phathom Pharmaceuticals' worth.Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.